Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance (Q43749263)

26 November 2017

title

Leukopenia predicts remission in patients with inflammatory bowel disease and Behcet's disease on thiopurine maintenance (English)

1 reference

inflammatory bowel diseases

26 November 2017

0 references

1 reference

8

1 reference

26 November 2017

Mi Sung Park

1

1 reference

26 November 2017

Dong Hyun Kim

2

1 reference

26 November 2017

Duk Hwan Kim

3

1 reference

26 November 2017

Soo Jung Park

4

1 reference

26 November 2017

Sung Pil Hong

5

1 reference

26 November 2017

Tae Il Kim

6

1 reference

26 November 2017

Won Ho Kim

7

1 reference

26 November 2017

publication date

20 September 2014

1 reference

Digestive Diseases and Sciences

26 November 2017

published in

1 reference

26 November 2017

volume

60

1 reference

26 November 2017

issue

1

1 reference

26 November 2017

page(s)

195-204

1 reference

Disease activity courses in a regional cohort of Crohn's disease patients

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

THE COURSE AND PROGNOSIS OF ULCERATIVE COLITIS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Inflammatory bowel disease in Korea: epidemiological, genomic, clinical, and therapeutic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

The clinical significance of a pathergy reaction in patients with Behcet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Long-term evolution of disease behavior of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Gastrointestinal manifestations of Behçet's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Azathioprine in inflammatory bowel disease, a safe alternative?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Rational dosing of azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Correlation of genotypes for thiopurine methyltransferase and inosine triphosphate pyrophosphatase with long-term clinical outcomes in Korean patients with inflammatory bowel diseases during treatment with thiopurine drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Outcome predictors for thiopurine maintenance therapy in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

A case of Crohn's disease with improvement after azathioprine-induced pancytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Comparison of leukocyte excretion and blood loss in inflammatory disease of the bowel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Is neutropenia required for effective maintenance of remission during azathioprine therapy in inflammatory bowel disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Neutropenia is not required for clinical remission during azathioprine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Immunity, inflammation, and allergy in the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

The immune system in the elderly: II. Specific cellular immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Thiopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S10620-014-3355-4

Patientsʼ attitudes to medicines and adherence to maintenance treatment in inflammatory bowel disease

21 January 2018

1 reference

12 December 2020

Ulcerative colitis: prolonged remission following azathioprine-induced pancytopenia.

1 reference

12 December 2020

Risk factors for non-adherence to medication in inflammatory bowel disease patients

1 reference

12 December 2020

Classification of inflammatory bowel disease

1 reference

12 December 2020

Optimum duration of treatment with 6-mercaptopurine for Crohn's disease

1 reference

12 December 2020

6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity

1 reference

12 December 2020

[The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease]

1 reference

12 December 2020

The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease

1 reference

12 December 2020

Development of consensus statements for the diagnosis and management of intestinal Behçet's disease using a modified Delphi approach

1 reference

12 December 2020

Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis

1 reference

12 December 2020

Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis

1 reference

12 December 2020

Azathioprine for maintaining remission of Crohn's disease

1 reference

12 December 2020

Significance of WBC differential when leukopenia is induced by 6-MP for IBD

1 reference

12 December 2020

A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease

1 reference

12 December 2020

Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcet's disease

1 reference

12 December 2020

Epidemiology of inflammatory bowel disease

1 reference

12 December 2020

Influences of thiopurine methyltransferase genotype and activity on thiopurine-induced leukopenia in Korean patients with inflammatory bowel disease: a retrospective cohort study

1 reference

12 December 2020

10.1007/S10620-014-3355-4

Identifiers

DOI

1 reference

26 November 2017

1 reference